Related Experiment Video
Updated: Jun 21, 2025
07:23
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
252
The Target Therapy Hyperbole: "KRAS (p.G12C)"-The Simplification of a Complex Biological Problem
Massimiliano Chetta1, Anna Basile2, Marina Tarsitano1
1U.O.C. Medical and Laboratory Genetics, A.O.R.N., Cardarelli, 80131 Naples, Italy.
Cancers
|July 13, 2024
Summary
KRAS gene mutations drive many cancers. While Sotorasib targets KRAS p.G12C, its efficacy is complex. This study reveals distinct structural dynamics of KRAS isoforms and mutations, impacting therapeutic strategies.
Area of Science:
- Oncology
- Molecular Biology
- Computational Chemistry
Background:
- Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) gene mutations are implicated in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC).
- Targeting KRAS has been challenging due to the absence of typical drug-binding sites, although specific inhibitors like Sotorasib for the p.G12C mutation have emerged.
- Recent clinical trial data (CodeBreaK 200) showed no significant overall survival benefit for Sotorasib over Docetaxel in NSCLC, underscoring the complexity of KRAS-targeted therapy.
Purpose of the Study:
- To compare the three-dimensional structures of KRAS4A and KRAS4B isoforms.
- To investigate structural alterations in Sotorasib's binding pocket caused by common KRAS mutations (p.G12C, p.G12D, p.G12V).
- To elucidate the impact of these structural variations on KRAS aggregation propensities and oligomeric states.
Main Methods:
- Three-dimensional structural comparison of KRAS4A and KRAS4B.
- Computational analysis of structural changes induced by KRAS mutations (p.G12C, p.G12D, p.G12V) within the Sotorasib-binding domain.
- Assessment of aggregation propensities and oligomeric configurations for wild-type and mutant KRAS isoforms.
Main Results:
- Distinct three-dimensional structures were identified for KRAS4A and KRAS4B isoforms.
- Computational analysis revealed probable structural changes in Sotorasib's pocket domain due to KRAS mutations.
- Wild-type and mutant KRAS isoforms exhibited different aggregation propensities, leading to varied oligomeric configurations.
Conclusions:
- The structural dynamics of KRAS isoforms and their mutations present significant complexity for therapeutic targeting.
- A deeper understanding of KRAS structural behavior is crucial for designing more effective anti-cancer drugs.
- Computational approaches offer valuable insights into KRAS-mediated oncogenesis and can aid in developing novel therapeutic strategies.
Related Concept Videos
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:59CRISPR
50.4K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
50.4K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:26Protein Networks
3.9K
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
3.9K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
02:53CRISPR and crRNAs
16.9K
Bacteria and archaea are susceptible to viral infections just like eukaryotes; therefore, they have developed a unique adaptive immune system to protect themselves. Clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins (CRISPR-Cas) are present in more than 45% of known bacteria and 90% of known archaea.
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
16.9K